EUCTR2017-003765-10-IT进行中（未招募）1 期
Immunotherapy Followed By EGFR Inhibitor In Locally Advanced Or Metastatic Squamous Cell Cancer Of The Skin: Tackling Primary And Secondary Resistance - I-TACKLE
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 43
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Have histological diagnosis of squamous cell carcinoma of the skin not amenable to surgical treatment and to radiation with curative purposes or with clinical contraindication to surgery and radiation. Hereafter the possible clinical situations matching these criteria. A multidisciplinary evaluation with surgeon, radiation oncologist and medical oncologist is required to be performed:
- •¿ skin SCC that has recurred in the same location after two or more surgical procedures and curative resection is deemed unlikely; the tumor is not amenable to radiation as it has been already performed or it is not considered effective
- •anticipated substantial morbidity and/or deformity from surgery (e.g., removal of all or part of a facial structure, such as nose, ear, eyelid, eye; or requirement for limb amputation); radiation therapy is similarly not indicated due to anticipated morbidity and/or deformity
- •¿ anticipated difficulty in obtaining a curative resection or a curative radiation due to the location of the tumor, the size of disease
- •¿ anticipated difficulty in reconstructing the area that will be surgically removed
- •¿ significant comorbidities that preclude the feasibility of a radical surgery
- •¿ contraindication to radiotherapy:
- •a) previous radiation therapy administered to the area of disease
- •b) site of previous burns
- •c) areas of vascular insufficiency
- •d) skin areas which lead to compromised healing or increased risk of late skin necrosis (e.g.: skin of the back overlying the spine; skin overlying the shin and malleoli of the lower leg)
- •e) patients with ataxia telangiectasia or with xeroderma pigmentosus
- •f) other contraindications according to physician’s judgement (to be reported in clinical chart)
- •Have metastatic disease
- •2.Have measurable disease based on RECIST 1.1.
- •3.Be willing to provide tissue from a newly obtained core or excisional biopsy of a tumor lesion. Newly-obtained is defined as a specimen obtained up to 6 weeks (42 days) prior to initiation of treatment on Day 1. Subjects for whom newly-obtained samples cannot be provided (e.g. inaccessible or subject safety concern) may submit an archived specimen only upon agreement from the Sponsor.
- •4.Have a performance status of 0 or 1 on the ECOG Performance Scale.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 33
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •1.Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
- •2.Previous treatment with anti-EGFR agent
- •3.Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (prednisone equivalent dose > 10 mg per day) or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
- •4.Has a known history of active TB (Bacillus Tuberculosis)
- •5.Has previously received an organ transplant
- •6.Has previously received bone marrow transplantation
研究者
相似试验
暂停
2 期
Panitumumab as second line therapy for advanced pancreatic ductal adenocarcinoma with wild-type KRAS geneKRAS wild-type unresectable or metastatic pancreatic ductal adenocarcinomaCancer - PancreaticACTRN12617000540314Dr Daniel Croagh24
进行中（未招募）
1 期
Rational Anti-EGFR therapy Selection for the first-line treatment of patients with metastatic KRAS/NRAS wild type colorectal cancer based on the use of molecular predictor miR-31-5p (RASmiR)inoperable, untreated, wild type RAS (wt KRAS/wtNRAS), metastatic colorectal cancer (mCRC)EUCTR2018-001210-15-CZMasarykuv onkologický ústav375
撤回
2 期
Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast CancerAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Breast Inflammatory CarcinomaInvasive Breast CarcinomaPrognostic Stage III Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Prognostic Stage IIIB Breast Cancer AJCC v8Prognostic Stage IIIC Breast Cancer AJCC v8Prognostic Stage IV Breast Cancer AJCC v8Triple-Negative Breast CarcinomaNCT05177796M.D. Anderson Cancer Center
招募中
2 期
Phase II Study of Local Therapy Combined with Immune Checkpoint Inhibitor for Oligo-Progressive disease during First-line Immunotherapy in non-small cell lung canceron-small cell lung cancerOligo-Progressive diseaseJPRN-jRCTs031220630Takahashi Kazuhisa60
Unknown
2 期
Phase II Clinical Study of Intermittent High Dose of Icotinib in Combination With Docetaxel to Treat Lung CancerNon Small Cell Lung CancerNCT02191059Shandong Cancer Hospital and Institute60